Kala Bio KALA
NASDAQ KALA
$0.18 +0.02 (+13.26%)
As of: Nov 9, 2026 · 2:42 PM EST

Kala Bio (KALA) Sale and Maturity of Investments (2021 - 2022)

Updated

Kala Bio (KALA) posted Sale and Maturity of Investments - Total of $10 million for FY2023, up 100.0% from $5 million in FY2022.

Analysis

Kala Bio (KALA) Sale and Maturity of Investments (2021 - 2022) Analysis & Trends

Since FY2020, Kala Bio has reported Sale and Maturity of Investments - Total for 4 years.

  • Annual Sale and Maturity of Investments - Total shows a three-year compound annual growth rate of -35.5% (FY2020 to FY2023).
  • Annual Sale and Maturity of Investments - Total has run from a low of $5 million in FY2022 to a high of $76.25 million in FY2021 over five years.
  • Business Quant data shows KALA's Sale and Maturity of Investments - Total at $5 million in FY2022 (-93.4%), $76.25 million in FY2021 (+104.3%) and $37.33 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Investments Sold (Qtr)
1 Eli Lilly 1,261.91 Bn 1,235.52 Bn 20.46 Bn -
2 Johnson & Johnson 679.68 Bn 599.54 Bn 17.30 Bn 308.00 Mn
3 AbbVie 518.95 Bn 486.95 Bn 13.12 Bn -
4 Merck 366.60 Bn 329.54 Bn 13.19 Bn 405.00 Mn
5 Novartis Ag 317.41 Bn 290.65 Bn - 88.00 Mn
6 Astrazeneca 293.70 Bn 267.59 Bn 13.26 Bn -
7 Amgen 251.07 Bn 202.73 Bn 7.58 Bn -
8 Gilead Sciences 210.48 Bn 185.59 Bn 6.73 Bn -
9 Pfizer 168.15 Bn 115.51 Bn 12.56 Bn 2.53 Bn
10 Kala Bio 2.68 Mn -41.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 2.00 Mn
Sep 30, 2021 5.00 Mn
Jun 30, 2021 23.00 Mn
Mar 31, 2021 48.25 Mn
API Access

Kala Bio Sale and Maturity of Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sale-and-maturity-of-investments&ticker=KALA&period=max&api_key=YOUR_API_KEY